Biogen Inc. (NASDAQ:BIIB) Shares Bought by Bogart Wealth LLC

Defense World · Oct 3, 2022 19:02

Bogart Wealth LLC raised its stake in Biogen Inc. (NASDAQ:BIIB – Get Rating) by 1,150.0% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 200 shares of the biotechnology company's stock after acquiring an additional 184 shares during the quarter. Bogart Wealth LLC's holdings in Biogen were worth $41,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of BIIB. PDT Partners LLC acquired a new position in shares of Biogen during the 4th quarter worth approximately $587,000. Adage Capital Partners GP L.L.C. raised its stake in shares of Biogen by 60.5% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 181,499 shares of the biotechnology company's stock worth $43,545,000 after buying an additional 68,400 shares during the period. Cubist Systematic Strategies LLC raised its stake in shares of Biogen by 136.5% during the 4th quarter. Cubist Systematic Strategies LLC now owns 30,668 shares of the biotechnology company's stock worth $7,358,000 after buying an additional 17,700 shares during the period. Cinctive Capital Management LP raised its stake in shares of Biogen by 11.0% during the 4th quarter. Cinctive Capital Management LP now owns 5,034 shares of the biotechnology company's stock worth $1,208,000 after buying an additional 500 shares during the period. Finally, Credit Agricole S A raised its stake in shares of Biogen by 73.4% during the 4th quarter. Credit Agricole S A now owns 607 shares of the biotechnology company's stock worth $146,000 after buying an additional 257 shares during the period. 83.45% of the stock is owned by institutional investors and hedge funds.

Get Biogen alerts:

Biogen Price Performance

BIIB stock opened at $267.00 on Monday. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.94 and a quick ratio of 1.68. The firm has a market capitalization of $38.75 billion, a P/E ratio of 19.04, a P/E/G ratio of 1.62 and a beta of 0.16. The business's 50-day moving average is $211.47 and its two-hundred day moving average is $208.53. Biogen Inc. has a 1 year low of $187.16 and a 1 year high of $290.76.

Biogen (NASDAQ:BIIB – Get Rating) last posted its quarterly earnings results on Wednesday, July 20th. The biotechnology company reported $5.25 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.09 by $1.16. The company had revenue of $2.59 billion for the quarter, compared to analyst estimates of $2.48 billion. Biogen had a return on equity of 22.36% and a net margin of 19.36%. Biogen's revenue for the quarter was down 6.7% compared to the same quarter last year. During the same quarter last year, the company earned $5.68 EPS. Analysts anticipate that Biogen Inc. will post 16.44 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently commented on BIIB. Wells Fargo & Company increased their price objective on Biogen from $265.00 to $350.00 and gave the company an "overweight" rating in a research note on Wednesday, September 28th. JPMorgan Chase & Co. increased their price objective on Biogen from $221.00 to $275.00 in a research note on Friday. StockNews.com raised Biogen from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, July 27th. Truist Financial reduced their price objective on Biogen from $270.00 to $265.00 and set a "buy" rating for the company in a research note on Thursday, September 22nd. Finally, Piper Sandler increased their price objective on Biogen from $200.00 to $280.00 and gave the company a "neutral" rating in a research note on Wednesday, September 28th. Ten analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $275.50.

Biogen Profile

(Get Rating)

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis.

Biogen Inc. (NASDAQ:BIIB) Shares Bought by Bogart Wealth LLC

Biogen Price Performance

Wall Street Analyst Weigh In

Biogen Profile

See Also

Risk Disclaimer